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ABSTRACT 
 
MicroRNA Expression in Canine Mammary Cancer.  
(May 2008) 
René Michelle Boggs, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Keith Murphy 
 
MicroRNAs (miRNAs) play a vital role in differentiation, proliferation and 
tumorigenesis by binding to messenger RNAs (mRNA) and inhibiting translation.   To 
initiate an investigation into the identification of miRNAs in the domestic dog, an 
emerging model for human disease, a comparison of the human and canine genetic 
databases was conducted.  The bioinformatics work revealed significant conservation of 
miRNA genes between the two species.  Proof of principle experiments, including serial 
dilutions and sequencing, were performed to verify that primers made to amplify human 
mature miRNAs can be used to amplify canine miRNAs, providing that the mature 
sequences are conserved. TaqMan® Real-time RT-PCR, a sensitive and specific method, 
was used to isolate the first miRNA mature products from canine tissues. The expression 
levels of miR-17-3p, miR-17-5p, miR-18, miR-19a, miR-19b, miR-20, and miR-92 were 
evaluated in five canine tissues (heart, lung, brain, kidney, and liver). Because miRNAs 
have been found to act as both tumor suppressors and oncogenes in several different 
cancers, expression patterns of ten miRNAs (miR-15a, miR-16, miR-17-5p, miR-21, miR-
29b, miR-125b, miR-145, miR-155, miR-181b, let-7f) known to be associated with 
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human breast cancer were compared between malignant canine mammary tumors (n=6) 
and normal canine mammary tissue (n=10). Resulting data revealed miR-29b and miR-21 
to have a statistically significant (p<0.05) up-regulation in cancerous samples.  Overall 
expression patterns showed nine of the ten miRNAs follow the same pattern of 
expression in the domestic dog as the human, while the miR-145 expression does not 
show a difference between the normal and cancerous samples.   
v 
 
DEDICATION 
 
To Mr. Firgens, Mrs. Dooley, Mr. Tobias, and Dr. Durham, my secondary 
science and math teachers who not only encouraged but inspired while consistently 
pushing me to be a better student and a better person 
vi 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my committee chair, Dr. Keith Murphy, and my committee 
members, Dr. Weston Porter, Dr. Charles Long, Dr. Ann Kier, and Dr. James Womack, 
for their guidance and support throughout the course of my graduate career. I look 
forward to our future collaborations.  And thanks to Drs. Charles Scanlan and Tawfik 
Omran for giving me my start in the Veterinary Microbiology Laboratory.   
Thanks also go to my friends and colleagues at Texas A&M University.  I would 
like to recognize the Canine Genetics Laboratory and the entire Department of 
Veterinary Pathobiology, especially the administrative staff who kept my records 
straight and a business permit handy.  Thanks to Patsy Story, Ali Wilkerson, Drs. 
Stephanie Herbst, Jan Janecka, and Rick Metz and soon-to-be Drs. Christine New, 
Jacquelyn Wahl, Elizabeth Wellberg, and Brian Laffin who kept me laughing and 
smiling even when experiments were failing.  And to my “partner-in-crime” Jessica 
Moody, you are a mentor, editor and friend.  This project and my maintained sanity 
could not have happened without you. A special thanks to Drs. Zachary Wright and 
Mark Stickney who collaborated on the mammary cancer project, and to the Kier Lab for 
the use of the real time machine for the initial experiments. I want to extend my gratitude 
to the Canine Health Foundation which provided partial funding for this project.   
Finally, thanks to my parents, Richard and Velma Sauer, and my husband, 
Captain Nicholas Boggs.  You have always believed in me, been there for me, 
encouraged me, and reminded me of what is really important: family and love. 
vii 
 
NOMENCLATURE 
 
3' UTR 3' untranslated region 
AIB1 Amplified in Breast Cancer 1  
CT critical threshold 
dsRNA double stranded RNA 
ER estrogen receptor 
HOXD10 homeobox D10  
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miRNA microRNA 
mRNA messenger RNA 
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pre-miRNA precursor microRNA 
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reaction 
R
2 
correlation value 
RISC RNA Induced Silencing Complex 
RH radiation hybrid 
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RNAi RNA interference  
RNA ribonucleic acid 
shRNA short hairpin RNA 
siRNA short interfering RNA 
TCF8 transcription factor eight 
TPM1 tropomyosin one 
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CHAPTER I 
INTRODUCTION 
 
The American Cancer Society estimates that 240,510 women will be diagnosed 
with breast cancer in 2007, making it the most frequently diagnosed cancer in American 
women (American Cancer Society 2007).  Another 40,460 will lose their battles with 
this disease (American Cancer Society 2007) that has become synonymous with the 
color pink and captured the attention and hearts of the public over the last two decades. 
Few can say that breast cancer has not directly or indirectly affected their lives.  While 
research continues to progress, and survival rates improve, much work is left undone and 
many questions remain unanswered.  Part of the investigation into breast cancer’s 
mechanisms involves the use of models.  Scientists have used the mouse (Mus 
musculus), rat (Rattus norvegicus), xenografts, and in vitro models with great success.  
Cellular pathways, new treatments and genetic aberrations have been elucidated with the 
aide of these models.  However, each approach has limitations, and thus the search 
continues for novel and improved models that more accurately represent human breast 
cancer.   
 
 
Current Model Systems 
 
 Cell lines, genetically engineered mice, and xenografts are the most common  
 
 
__________________ 
This dissertation follows the style of Mammalian Genome. 
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model systems used in breast cancer research.  Each system has its own advantages and 
disadvantages, allowing researchers to investigate different parts of the puzzle that is 
breast cancer.  Because cancer is a complex and heterogeneous disease, multiple systems 
are needed to elucidate progression of the disease and validate hypotheses. 
 Researchers would be lost without cell lines.  Breast cancer lines from both 
human and rodents are available, and many lines are immortalized.  An unending supply 
of protein, RNA, and DNA is a great advantage and allows for experiments to be 
replicated in mass.  Cell lines are relatively inexpensive to maintain, and are easily 
manipulated both genetically and chemically.  Human cell lines provide more direct 
subject evidence and confer the advantage of being directly from the species of study, 
providing more directly applicable answers.  Cell lines can also be transplanted into 
rodents using xenographs, enabling an in vivo study.  There are also different lines 
established that mimic many of the different subtypes of breast cancer.  Unfortunately, a 
single cell line, which is usually derived from a single cell type, does not recapitulate a 
typical primary tumor which consists of multiple cell types (epithelial, stromal, vascular, 
immune, etc.) with multiple aberrations. Thus, one cell line cannot mimic the highly 
heterogeneous environment that is found in breast tumors (Vargo-Gogola and Rosen 
2007).  Genome copy number abnormalities are much more common in tumors than in 
cell lines (Neve et al. 2006).  In addition, primary cell lines which are more 
representative of actual tumor cell life are difficult to cultivate and only survive for a few 
passages.  Cell lines are ideal for studies examining signal pathways and gene regulation, 
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but resulting data has to be confirmed in an in vivo model before application to human 
cancers. 
 Laboratory rodents are found in nearly every research institution because rapidly 
evolving genetic technology has enabled the production of hundreds of rodent lineages, 
each with a particular phenotype of interest.  The complete genome sequence and 
annotated assembly is available for the mouse and rat, and both of these mammals show 
high levels of conservation with the human genome (Gibbs et al. 2004; Waterston et al. 
2002).  Some strains of mice are slightly more prone to tumors in general, but breast 
cancer researchers typically use several genetically manipulated murine models.  
Mammary tumors in the rat are mainly studied through chemically induced approaches 
in breast cancer labs (Vargo-Gogola and Rosen 2007).  Their short life-span and large 
litter sizes are needed to carry out multiple-generation studies to identify heritable 
markers.  Mice are easy to breed, and matings can be manipulated and replicated.  There 
are a few disadvantages to this model system as well.  Tumors seem to have different 
tissue origins as compared to the human, and the tumors have fewer chromosomal 
abnormalities (Vargo-Gogola and Rosen 2007).  Mice strains are highly inbred, and have 
a metabolic rate that is seven times higher than that of the human (Dennis 2006).  The 
ends of murine chromosomes (telomeres) are longer than the humans’, because the 
telomerase activity is higher (Dennis 2006).  And finally, mice undergo 10
5
 fewer cell 
divisions during their lifetime as compared to the human (Dennis 2006).   
Another major complication to the mouse model is the use of the Mouse 
Mammary Tumor Virus (MMTV).  Often the promoter of this endogenous murine 
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retrovirus is used to overexpress a certain gene in a genetically modified mouse (Vargo-
Gogola and Rosen 2007).  The virus itself is an example of the high load of pro-viruses 
that are found in the mouse model that are not seen in the human.  To date a virus has 
not been associated with human breast cancer, although the relationship between the 
human papillomavirus and cervical cancer is documented in humans (Walboomers et al. 
1999).  One advantage to the induced tumor model is the ability to study how the tumor 
is initiated.  Other spontaneous models do not offer this advantage. 
 Xenografts consist of an injection of cells into a live animal, usually a rodent, in 
order to study the actions of the cells in an in vivo environment.  These are often used in 
metastasis research, and offer excellent insight into invasion properties and progression 
studies (Vargo-Gogola and Rosen 2007).  However, human cells may act differently in a 
rodent environment than they do in a human environment, limiting the insights that can 
be made. 
 All in all, these models are diverse and useful, each providing a different side to 
the cancer story.  However, in the currently used breast cancer models the tumors arise 
by methods such as mutagens or viral promoters that are not present in human breast 
tumor formation. Therefore a natural system of tumor induction would open a new door 
into breast cancer research.  The collective disadvantages, summarized in Table 1, 
encourage researchers to keep looking for another, better system. 
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Table 1. Breast Cancer Model Comparison. 
 
Model    
 
Cell lines 
 
 
 
 
 
 
                       
Xenograft 
 
 
 
                        
Mouse 
 
 
 
 
 
 
 
Rat 
 
 
 
 
Dog 
Advantages 
 
Multiple lines available from both 
rodent and human breast cancers 
Immortalized lines are easy to distribute, 
propagate, and store 
Cells can be genetically and chemically 
manipulated 
Helpful in studying proliferation and 
signaling pathways 
 
 
Allows the study of either primary or 
manipulated cells in an in vivo 
environment 
Excellent for studying invasion and 
metastasis 
 
 
Easy to breed, short life-span, and large 
litter sizes 
Complete genome sequenced 
Genetically manipulated to exhibit 
specific and desired breast cancer 
phenotypes 
Most commonly used laboratory animal  
 
 
 
Chemically induced tumor formation is 
helpful is studying the effects of 
carcinogens 
Complete genome sequenced 
 
 
Spontaneously occurring mammary 
tumors 
Share the same environment as humans, 
often serving as sentinels for 
environmental carcinogens 
Physically and genetically more similar 
to humans than either rodent model 
Complete genome sequenced 
Excellent health care facilities and 
medical records available with extensive 
pedigrees  
Shorter life-spans than humans and large 
litter sizes 
Large general population that is outbred 
Disadvantages 
 
Tumor cells are homogeneous, while 
actual tumors are heterogeneous 
Finding must be validated in an in vivo 
model 
Gene copy number aberrations are lower 
in cell lines than in tumors 
Primary cell lines are difficult to initiate 
and stabilize 
 
 
Human cells may not act the same way 
in a rodent environment as they would 
in a human environment 
 
 
 
 
For both rodent models: 
Higher metabolism and telomerase 
activity as compared to the human 
Tumors used in mammary research are 
induced; tumor origin is often in 
different tissues than in the human and 
with fewer chromosomal abnormalities  
Undergo fewer cell divisions in their 
lifetime versus the human 
Smaller anatomy/sample collections 
Highly inbred 
Tumor inducing viruses (MMTV) 
For the rat: 
No knockout strains have been created 
 
 
Transgenic models are not available 
Dependence on client owned animals 
may limit sample collections 
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The Domestic Dog as a Model 
 
One underused mammalian system is that of the domestic dog, Canis familiaris.  
For centuries the relationship between dog and man has been documented, but these two 
share more than just a common bond of friendship and loyalty.  The domestic dog is 
genetically closer to the human than any of the previously mentioned models  
 (Kirkness et al. 2003).  This discovery was made possible when the complete genomic 
sequence of the dog was made publicly available with 1.5X coverage in of the poodle in 
2002 (Kirkness et al. 2003).  The currently available sequence of the boxer, Tasha, has a 
7.5X coverage (Lindblad-Toh et al. 2005).  This means that this genome sequence was 
so complete, that the “gaps” present in the genome were sequestered to autosomes 2, 11, 
and 16 out of the 36 pairs of autosomes and 2 sex chromosomes present in the canine 
karyotype.  In addition to the karotype and sequence, detailed linkage and radiation 
hybrid (RH) maps are available and widely used (Breen et al. 2004; Guyon et al. 2003).  
Advances in computational analysis now allow researchers to critically evaluate and 
compare genomes across species to identify and investigate potential areas of interest, 
such as orthologous genes and conversed non-coding regions.  
Despite the fact that the dog’s ancestor diverged 93 million years ago from 
Euarchontaglires, the lineage that includes rodents and primates in the evolution tree 
(Murphy et al. 2001; Springer et al. 2003), the genome structure of the dog shows 
greater homology and conservation with the human as a result of the faster evolutionary 
rates observed in rodents (Wildman et al. 2007).  The physiology of the domestic dog 
provides model advantages as well.  The metabolism and cell kinetics of the dog have 
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greater similarity with the human, than those of rodents (Lana et al. 2007).  Thus both 
surgical and dosage studies can be more directly compared to human medicine.  While 
body size of the dog varies greatly, all breeds are bigger than rodents used in research 
providing larger organs and tissues from which samples can be taken and analyzed.   
 One of the greatest advantages to cancer studies, however, is that fact that tumors 
occur spontaneously in the domestic dog and have a similar progression to human breast 
tumor malignancies.  By avoiding chemical or genetic modifications to induce cancer (as 
is sometimes done in rodent models), the canine oncology model provides a “purer” 
example of the initiation and progression mechanisms of cancer cells.  Since pets share 
our environment and often our diet, dogs can and have acted as sentinels for 
carcinogens.  The dog’s shorter lifespan and large litter sizes allow for clinical trials that 
are vastly shorter than those in the human.  In addition, their population structure mimics 
that of the human, as they are generally outbred, but have subpopulations that underwent 
significant bottlenecks followed by inbreeding (Parker and Ostrander 2005).  Breed 
clubs often include highly inbred dogs with extensive pedigrees which are ideal study 
populations to tease out causative mutations or rare chromosomal abnormalities 
responsible for particular diseases.  Most relevant to the work presented in this 
dissertation however, is the fact that veterinary medical care has achieved great advances 
in order to make canine healthcare second to that of the human (Ostrander et al. 2000).  
Advances made in medical records and equipment have created in the opportunity to 
study and trace specific diseases, including canine mammary cancer. Table 2 compares 
the presentation of human breast cancer to canine mammary cancer.  
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Table 2. Canine Mammary Cancer vs. Human Breast Cancer. 
 
 Human Canine 
Statistics 
      Incidence 
      Overall lifetime risk 
 
~100/100,000 
16% 
 
~260/100,000 
2-20% 
Mammary Physiology 2 breasts 2 chains of 5 glands 
Cellular Origin Epithelial Epithelial 
Frequent Metastasis Site Lymph nodes and Lung Lymph nodes and Lung 
Inflammatory Carcinoma 
Subtype 
Yes Yes 
Molecular Changes: 
Genetic mutations/Aberrant 
expression profiles 
(BRCA1, c-erbB-2, etc.)  
    p53 mutations 
Chromosomal abnormalities 
in tumor cells 
 
Yes 
 
 
~20-25% 
Yes 
 
Yes 
 
 
~17% 
Yes 
Risk Factors: 
     Increased age 
     Female sex 
     Familial history 
     Sex hormone exposure 
     Obesity 
     Reduction of risk by  
     early pregnancy 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Not shown so far 
Effective Treatments 
     Surgery 
     Chemotherapy 
     Radiation 
     Anti-estrogen treatments 
 
Yes 
Yes 
Yes 
Yes 
 
Yes 
No 
Not studied 
No 
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Canine Mammary Cancer 
Incidence 
It is estimated, that there are over 74 million household dogs in the United States 
alone.  Because of advances in both human and veterinary medicine, the canine 
population, like the human population, is living longer, and this trend is one of the 
suggested theories of the rise in cancer in pets over the last few years (Lana et al. 2007).  
The rise in cancer could also be attributed to the technology that is now available, 
allowing for a more rapid and accurate diagnosis.  Canine mammary tumors are the most 
prevalent neoplasm in the intact bitch (Sorenmo 2003). Multiple studies (summarized in 
Table 3) have been undertaken to estimate the actual incidence values with conflicting 
results.  Approximately 260 out of every 100,000 dogs in the United States will be 
affected by mammary cancer every year if left intact (Dorn et al. 1968; Moulton et al. 
1986).   Analyzing the records of a pet-insurance company in the United Kingdom 
showed a similar yearly rate of incidence at 205 out of 100,000 dogs (Dobson et al. 
2002).  In contrast, a study of over 80,000 dogs in the Swedish population found an 
incidence of 111 cases out of every 10,000 dog years at risk (Egenvall et al. 2005).  Most 
investigations into incidence agree that several breeds have higher rates of mammary.   
cancer suggesting a hereditary link, these include the poodle, English springer spaniels, 
 
Brittany spaniels, cocker spaniels, English setters, pointers, German shepherds, Maltese, 
 
Yorkshire terriers, dachshunds, Golden retrievers and Doberman pinchers (Egenvall et 
al. 2005). 
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Table 3.  Incidence of Canine Mammary Cancer.  Estimations of dogs diagnosed/year 
are summarized below. 
 
   Incidence  Country 
 
260/100,000  United States 
 
205/100,000  United Kingdom 
 
111/10,000  Sweden 
 
 
 
  While it was estimated that 48% of the canine mammary tumors are benign, the 
remaining 52% are malignant (Fidler and Brodey 1967).  However, recent literature 
places the malignancy rate anywhere from 41-53% (Fidler and Brodey 1967; Gilbertson 
et al. 1983).  There is however, a very high recurrence rate, in that half of the tumors 
treated with surgery, later regenerate the tumor or develop a distant metastasis (Fidler 
and Brodey 1967).  It is estimated that American female dogs have a 2-20% lifetime risk 
of developing canine mammary cancer at some point in their lives (Dorn et al. 1968; 
Moulton et al. 1986).  Recent work has shown a higher incidence of malignant tumors in 
large dogs (58%) versus the small breeds (25%) (Itoh et al. 2005).  This work is 
controversial though, and has yet to be further confirmed. 
Pathology and Treatment 
 Mammary tumors in the dog are either benign or malignant, and within these two 
classifications are several subtypes dependent upon their tissue of origin (e.g., epithelial, 
mesenchymal, or myoepithelial), cellular structure, invasiveness and exact location (e.g., 
duct, lobules, etc.) (Lana et al. 2007).  As in human breast cancer, most canine mammary 
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tumors are epithelial in origin (Sorenmo 2003).  Approximately 65-70% of the canine 
mammary tumors occur in the caudal 4
th
 or 5
th
 gland, and more than 60% of cases have 
more than one tumor present in the mammary chain at the time of diagnosis (Benjamin 
et al. 1999; Fowler et al. 1974).  Canine mammary tumors primarily metastasize to the 
sublumbar, sternal and prescapular lymph nodes and to the lungs; however, metastasis to 
the liver and kidneys is not uncommon, while bone metastasis is rare (Lana et al. 2007; 
Misdorp and den Herder 1966). 
 Inflammatory mammary carcinoma (IMC) is a particularly aggressive form of 
mammary cancer found to only naturally occur in the human and the dog (Lana et al. 
2007).  This subtype accounts for 17% of malignant canine cases and is characterized by 
poorly differentiated, estrogen receptor negative cells (Pena et al. 2003a; Pena et al. 
2003b; Perez Alenza et al. 2001).  IMC rapidly invades the lymphatic system and 
metastasizes, resulting in very low and short survival times (Lana et al. 2007). 
 While several treatments exist, surgical removal of the tumor is the most 
common approach, but as previously mentioned, has only ~50% success rate (Fidler and 
Brodey 1967).  Surgical therapies contain vast variances as well, ranging from simple 
lumpectomies, recommended for small, non-invasive tumors to radical uni- or bilateral 
chain mastectomies, recommended for large, multiple, invasive cases (Lana et al. 2007).  
There is ongoing debate as to whether radical chain mastectomies or local excisions are 
the better course of action, but the majority of investigations have shown no difference 
in reoccurrence or survival rates, as long as the entire neoplastic tissue is removed 
(Chang et al. 2005; MacEwen et al. 1985). 
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 Chemotherapy following surgical excision is the predominant choice of human 
physicians to treat breast cancer (Dickson et al. 2005).  Unfortunately, this course of 
therapy is not widely accepted in veterinary practice as an effective course of action.  
Doxorubicin has been studied in both in vitro and in vivo experiments in the domestic 
dog with moderate success (Hershey et al. 1999; Karayannopoulou et al. 2001; Sartin et 
al. 1993; Simon et al. 2006).  Two studies have found that Doxorubicin effectively 
prolongs survival times of patients with particularly high grade mammary tumors and in 
cases with pulmonary metastasis (Hershey et al. 1999; Simon et al. 2006).  One 
investigation showed that treatment with cyclophosphamide and 5-fluouroucil after 
surgery prolonged survival by an average of 18 months (Karayannopoulou et al. 2001).  
This data is promising, but more and larger studies must be completed and published 
before the standard treatment protocol will change. 
 Other human treatments, such as radiation therapy and biologic response 
modifiers have either not be tested or have not proven effective in canine cases.  
Radiation therapy, which is used in humans when breast-sparing surgery is performed, 
may be a key player in low recurrence rates, but, to date, canine mammary cancer case 
studies using radiation therapy have not been published.  Biologic response modifiers, 
such as levamisole, lipo muramyl-tripeptide phosphatidylethanolamine, and 
Corynebacterium parvum with bacillus Calmette-Guérin, have not proven effective 
when tested in canine mammary cancers (MacEwen et al. 1985; Parodi et al. 1983).  
 Antiestrogen therapies, such as tamoxifen, are not recommended as treatment 
modalities in canine cancers (Lana et al. 2007).  While antiproliferative activity was 
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detected in canine in vitro studies, multiple clinical trials have shown devastating side-
effects when used on dogs such as incontinence, signs of estrus, fluid and infections of 
the uterus or urinary tract, swelling of the vulva, and vaginal discharge (Morris et al. 
1993).  Hormones do play a clear role in canine cancer, though.  It is irrefutable that 
ovariohystorectomies (OHEs) preformed prior to the first estrus cycle reduce the risk of 
canine mammary cancer.  If the OHE is done before the first estrus, there is a 0.5% risk 
of mammary cancer (Schneider et al. 1969).  The risk rises to 8% if the OHE is spayed 
after the first estrus, and 26% if spayed after the second estrus (Schneider et al. 1969).  
However, OHE as a treatment in dogs suffering from mammary cancer does not seem to 
result in longer survivals (Morris et al. 1998; Yamagami et al. 1996).  Although, one 
retrospective study did show an increase in survival time if the OHE is performed in the 
two years before the first malignant tumor removal (Sorenmo et al. 2000).  Overall, later 
spaying does not seem to reduce malignant tumor survival or incidence.   
 The two key hormones in both human and canine mammary cancer studies are 
estrogen and progesterone.  Estrogen is known to stimulate ductal growth, while 
progesterone and synthetic progestins such as chlormadine acetate and 
medroxyprogesterone acetate are known to induce lobuloalveolar mammary 
development and hyperplasia of secretory and myoepithlial elements (Lana et al. 2007).  
The level of estrogen receptors (ER) and progesterone receptors (PR) differ between 
normal, benign and malignant canine mammary tissues.  In a study of 85 cancer and 10 
normal mammary tissue samples from 57 dogs, immunohistochemistry was used to 
detect receptors (Millanta et al. 2005).  100% of the normal and 95% of the benign 
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samples showed strong ER staining, while 62% of invasive tumors showed some ER 
staining and 38% of invasive tumors showed poor to no ER staining.  PR staining was 
lower in all tumors versus normal mammary tissue.  Another study used 
immunohistochemistry to analyze 228 tumors from 100 dogs (de Las Mulas et al. 2005).  
96% of the benign tumors showed staining for either PR or ER, while only 66% of the 
malignant tumors showed any staining.  100% of the cases where lymph node metastasis 
was detected were both ER and PR negative.  Other studies corroborate with the general 
consensus that benign canine mammary tumors and normal canine mammary tissue have 
higher amounts of estrogen receptors than malignant canine mammary tumors (de Las 
Mulas et al. 2005; Donnay et al. 1995; Illera et al. 2006; Kumaraguruparan et al. 2006; 
MacEwen et al. 1982; Millanta et al. 2005; Nieto et al. 2000; Queiroga et al. 2005b; 
Rutteman et al. 1988b; Sartin et al. 1992).  The fact that most canine malignant tumors 
seem to lose their hormone dependence during their progression to malignancy makes 
them an ideal model for human non-hormone dependent breast cancers.   
 The production or injection of progesterone is also known to increase the 
incidence of benign mammary tumors in the dog, with only one report suggesting it may 
also increase the incidence of malignant tumors (Stovring et al. 1997).  This increase 
may be linked to the increase in secretion levels of growth hormone in human and canine 
mammary tissue when progesterone levels rise.  Higher progesterone concentrations also 
coincide with rises in insulin-like growth factors I and II (IGF-I and IGF-II) in the 
human, mouse and dog, as well as in canine mammary tumor cell line studies (Mol et al. 
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1997).  The rise in IGF is also implicated in cell proliferation and tumorigenesis roles as 
well (Mol et al. 1997).   
Genetics and Other Risk Factors 
 Predisposition in certain breeds indicates that there may be a genetic component 
to canine mammary tumor development.  Like human oncology studies, several genetic 
links have been established in the dog model, many of which have homologs in the 
human genome.  P53 is the most commonly mutated gene in human cancers (Bourdon 
2007).  When investigated using canine mammary tumors samples, several mutations 
have been documented in the canine homolog of P53 (Chu et al. 1998; Van Leeuwen et 
al. 1996; Veldhoen et al. 1999).  Mutations of this major tumor suppressor gene are 
estimated to have an incidence of 17% in canine mammary cancers, with only one germ-
line mutation documented (Veldhoen et al. 1999). 20-25% of invasive human breast 
cancers are predicted to have a P53 mutation(Lacroix et al. 2006).  When comparing 
expression of P53, one study used multiple human antibodies and found that 15 out of 
20 mammary tumors exhibited an increase in expression of mutant p53 (Haga et al. 
2001).   
 Other genes, such as BRCA1 and the ras family have also been studied in the dog 
(Castagnaro 1995; Nieto et al. 2003).  While there are no reports of mutations in the ras 
family or increased expression of ras, mutations have been documented in BRCA1 in the 
dog (Nieto et al. 2003).  BRCA1 was cloned and sequenced because of the genetic link 
found in human breast cancer (Miki et al. 1994).  The loss of this gene in canine studies 
coincides with increased amounts of cell proliferation and ER negative staining (Nieto et 
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al. 2003).  When looking at the protein BRCA1, normal epithelial tissue shows nuclear 
staining, while tumors show mainly cytoplasmic staining, a phenomenon also 
documented in human studies (Nieto et al. 2003).   
 The oncogene c-erbB-2 has been documented to play a role in human breast 
cancer (Iwata 2007).  Specifically it has been shown to be overexpressed in cancers that 
respond well to Herceptin
TM
 (i.e. trastuzumab) because of its interaction with the 
receptor gene HER2 (Iwata 2007).  Canine studies have shown increased levels of both 
the protein and mRNA of c-erbB-2 in malignant but not in normal or benign tissues 
(Ahern et al. 1996; Dutra et al. 2004; Rungsipipat et al. 1999a).  The human oncogenes 
COX-2 and c-yes-1 have also been documented to be aberrantly expressed in canine 
mammary cancers (Dore et al. 2003; Heller et al. 2005; Miyoshi et al. 1991; Queiroga et 
al. 2005a; Rungsipipat et al. 1999a; Rungsipipat et al. 1999b).   
 Four heat shock proteins (Hsp27, Hsp72, Hsp73, and Hsp90) were analyzed 
using canine mammary tissue from 3 normals and 30 malignant cases (Romanucci et al. 
2006).  Hsp27, Hsp72 and Hsp90 were found to be overexpressed in tumors with a 
suggested role in carcinogenesis, while Hsp73 was suggested to play a role in cancer 
invasiveness.  Immunohistochemical studies showed that proliferating cell nuclear 
antigen, Bcl-2, p53, and ER expression is increased in canine mammary cancer versus 
normal tissue, while cytokeratin expression is decreased in the tumors 
(Kumaraguruparan et al. 2006).  The profile the staining created was mimicked using 
human samples.  DNA aneuploidy has also been studied in mammary tumors resulting in 
detections of deletions, trisomies, fusions, translocations and other cytogenetic 
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anomalies that likely play a role in the cancer progression (Hellmen et al. 1993; 
Rutteman et al. 1988a).   
 Other risk factors for canine mammary cancer include sex (obvious increased 
incidence in females), age (greater than 6 years of age) and obesity (Egenvall et al. 2005; 
Hellmen et al. 1993; Laumbacher et al. 2006; Perez Alenza et al. 1998; Sonnenschein et 
al. 1991).  Studies have shown an increased risk of mammary cancer, if dogs are 
overweight when they are 1-2 years of age, regardless of whether they are intact or 
spayed (Perez Alenza et al. 1998).  All three risk factors are also found to be of concern 
in the human.  The reduction in the incidence of mammary cancer after an early age of 
pregnancy that has been documented in human studies has not been proven to be an 
effective risk reduction in dogs (Kurzman and Gilbertson 1986). 
Prognosis 
 Currently, tumor size and grade are the leading prognostic indicators (Lana et al. 
2007).  A larger and more invasive tumor usually corresponds to a shorter survival time 
(Lana et al. 2007).  Nuclear differentiation, a low cell proliferation index, clean lymph 
nodes, and positive ER status of the tumor are generally regarded with as good prognosis 
factors, and the reverse status is associated with a poor prognosis (Kurzman and 
Gilbertson 1986; Lana et al. 2007).  
 
MicroRNAs 
Recent work in oncology revealed that many genes encoding tumor suppressors 
and oncogenes are regulated by a special class of non-coding RNA genes, named 
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microRNAs (Esquela-Kerscher and Slack 2006).  MicroRNAs (miRNAs) are 
endogenously produced by eukaryotic organisms and invoke the RNA interference 
(RNAi) pathway to effect posttranscriptional gene silencing.  The first miRNA was 
discovered in 1993 in Caenorhabditis elegans (Lee et al. 1993).  This gene, lin-4, codes 
for a short RNA sequence that first forms a hairpin and is later processed to a short, 22 
nucleotide, double-stranded RNA (dsRNA) segment that is complementary to the 3 
untranslated region (3 UTR) of the lin-14 transcript (Lee et al. 1993).  Research showed 
that the lin-4 RNA product reduced expression of the lin-14 gene (Wightman et al. 
1993).  This miRNA gene was thought to be unique, but seven years later, another 
miRNA, let-7, was discovered in C. elegans (Reinhart et al. 2000).  Subsequently, 
homologs of let-7 were found in the genomes of thirteen other organisms, giving the first 
clue to scientists that these conserved, novel genes play a crucial role in cellular 
pathways (Pasquinelli et al. 2000).  To date, over 500 miRNA sequences have been 
identified in the human genome (Griffiths-Jones et al. 2006), and because of the great 
conservation between the human and canine genomes, it is highly probable that these 
sequences are also present in the canine genome.  Thus, the approaches to investigate 
human miRNA expression can also be used to study miRNA expression in the dog.  The 
methods by which miRNA genes are transcribed and the mechanisms by which they 
regulate translation have been studied extensively in mammalian cells (Ambros 2004; 
Aravin and Tuschl 2005; Bartel 2004).   
The initial step for miRNA biogenesis is transcription by RNA polymerase II 
(Figure 1).  The resulting RNA strand is designated a “primary-miRNA” (pri-miRNA).   
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The single stranded RNA is modified, as are messenger RNAs (mRNAs), with a 5 cap 
and a polyadenylated tail.  The pri-miRNAs are usually several kilobases in length and 
contain imperfect stem-loop structures that resemble hairpins.   In step 2, the pri-
miRNAs are recognized by Drosha, an enzyme that cleaves the RNA sequence, leaving 
only the hairpin structure behind.  Drosha is a member of the RNase III family that 
characteristically leaves a two nucleotide overhang.  The cleaved sequence is now 
referred to as a “precursor-miRNA” (pre-miRNA).  The pre-miRNA is exported to the 
cytoplasm by a nuclear export factor, exportin 5, as shown in step 3.  Once in the 
cytoplasm, another RNase III enzyme, Dicer, recognizes the pre-miRNA and further 
cleaves the hairpin to leave only a short, 18-24 nucleotide, dsRNA sequence (step 4).  
Finally, the RNA-induced silencing complex (RISC) incorporates the RNA duplex into 
its complex set of proteins during step 5.  Only one strand remains associated and is used 
as a template to bind to the complementary portion of the target mRNA.  The 
incorporated RNA segment is referred to as the mature miRNA.  It is also interesting to 
note that many miRNAs target the 3'UTR of mammalian genes, a noncoding section of 
the gene.  When RISC is associated with the appropriate, protein-coding mRNA 
sequence, the miRNA pathway can take one of two routes. In general, if the mRNA is 
completely complementary to the mature miRNA, the mRNA is degraded.  If 
complementarity is not complete, the attachment to the mRNA is still able to reduce 
expression.  The RISC complex’s size and attachment location makes it difficult for 
translational machinery to stably attach to the mRNA (Thermann and Hentze 2007).  
Thus, protein production is reduced regardless of the route taken by the miRNA.   
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Oncomirs and Breast Cancer   
More than 50% of computational and experimentally identified miRNA genes 
are located in cancer-associated genomic regions, often called “fragile sites”(Calin et al. 
2004b).  Breaks and rearrangements of DNA occur more often in “fragile sites” and are 
thus areas of serious investigation.  miRNAs that are associated with cancers are 
collectively referred to as “oncomirs.”  The miRNAs may act as either tumor 
suppressors by targeting the mRNA of an oncogene, or they can take on the reverse role 
of an oncogene by targeting the mRNA of a tumor suppressor.  Because inhibition of 
translation can occur without perfect complementarity between the mature miRNA and 
the target mRNA, one miRNA can have several targets, and conversely, one mRNA may 
be targeted by several miRNAs.  This makes functional studies a bit more complicated, 
especially since the expression profiles of miRNAs have tissue specificity.  Several 
computational programs (miRanda, PicTar, TargetScan, etc.) exist to help predict likely 
targets and binding sites and have been used with success.   
The miR17-92 cluster of miRNA genes are differentially expressed in several 
types of cancer, including human mammary cancer tissues (Hossain et al. 2006; Volina 
et al. 2006; Zhang et al. 2006).  This specific cluster is made up of seven miRNA genes 
(miR-17-5p, miR-17-3p, miR-18, miR-19a, miR-19b, miR-20, miR-92) that arise from six 
miRNA precursors (miR-17-3p and miR-17-5p share the same precursor).  An 
investigation into gene copy number aberrations revealed that 21.9% of human breast 
cancers have the entire miR-17-92 cluster deleted (Zhang et al. 2006).  Specifically, the 
miR-17-5p gene was recently shown to affect cell proliferation in mammary cancer by 
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inhibiting the translation of the mRNA transcribed from Amplified in Breast Cancer 1 
(AIB1), a tumor suppressor gene (Hossain et al. 2006).  The same study also showed a 
very low expression of miR-17-5p in breast cancer cell lines.  Because of this action, it 
seems to fall into the category of a tumor suppressor miRNA.  O’Donnell and colleagues 
revealed the oncogene E2F1 to be another target of miR-17-5p (2005), and Lu and 
colleagues showed a down regulation of miRNA in breast cancer samples (2005).  
However, a microarray study by Volina et al. revealed an upregulation of the same 
miRNA in breast cancer (2006).  The differences could be explained by the different 
experimental techniques and analyses.  In addition, tumor samples can contain 
heterozygosity among themselves.  Thus, analyzing tumors by their specific pathology 
could account for differences in results as well. 
There are five basic classifications of human breast tumors, and they include the 
following: Luminal A, Luminal B, HER2+, Basal-like, and Normal-like (Neve et al. 
2006).  By looking at the general profile miRNA expression in these five subtypes, 
Blenkiron and colleagues were able to classify 51 out of 93 primary breast tumors using 
a bead-based flow cytometry method (2007).  Specifically, this study found a differential 
expression of miR-155 between ER positive and negative rumors.  In high grade (based 
upon size and invasion) tumors, the three miRNAs were found to be of interest: miR-
106b (a homolog of miR-17-5p), miR-93, and miR-25. A microarray study by Iorio and 
colleagues compared 79 human cancerous samples to ten normal tissue samples and 
revealed expression profiles that were able to identify normal and cancerous breast tissue 
based upon the differential expression of four miRNAs: miR-21, miR-145, miR-155, and 
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miR-125b (2005).  These results were confirmed by Northern blotting.  In addition, 
specific profiles were developed for several different factors involved in breast cancer 
including: ER/PR status, tumor grade, nodal involvement, vascular invasion, 
proliferation index and p53 expression.  Microarray and quantitative real time PCR 
(qRT-PCR) was used by Mattie et.al. in their investigation of tumors expressing 
different combinations of the receptors: ErbB2, ER and PR (2006).  Seven miRNAs 
were found to be expressed solely in the ErbB2 profile, including, let-7f and miR-10b.  
Four miRNAs were exclusive to the ER/PR status (miR-142-5p, miR-200a, miR-205, and 
miR-25).   
Some labs have chosen to investigate individual miRNAs in order to determine 
particular targets and functions in breast cancer.  Cimmino and colleagues recently 
confirmed that overexpression of miR-15a and miR-16-1 in a leukemic cell line model 
encourages tumor growth by posttranscriptionally suppressing the gene BCL2, which 
plays a critical role in apoptosis (2005).  miR-10b was found to target homeobox D10 
(HOXD10), a gene that represses the expression of RHOC (Ma et al. 2007).  When miR-
10b is expressed at high levels, the expression of RHOC, a pro-metastatic gene, 
increases; therefore, increased tumor invasion and metastasis occurs.  Interestingly, the 
transcription factor Twist was also found to induce miR-10b expression by binding to its 
promoter.  Another investigation revealed miR-200c to target transcription factor eight 
(TCF8), which regulates E-cadherin expression (Hurteau et al. 2007).  Estrogen receptor 
alpha has been shown to be regulated by both let-7d and miR-206 (Adams et al. 2007). 
Meanwhile, much attention has been given to miR-27a and miR-27b.  The former 
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miRNA acts as an oncogene by regulating Myt-1 and the specificity proteins Sp1, Sp2 
and Sp3, while the latter targets the oncogene, CYP1B1 (Mertens-Talcott et al. 2007; 
Tsuchiya et al. 2006).   
The most investigated oncomiR is miR-21.  Because it has found roles in several 
cancers including glioblastoma, liver, pancreatic, and breast, several studies have 
investigated its expression and function (Blenkiron et al. 2007; Esquela-Kerscher and 
Slack 2006; Frankel et al. 2007; Iorio et al. 2005; Jiang et al. 2005; Kovalchuk et al. 
2007; Lu et al. 2005; Mattie et al. 2006; Meng et al. 2007; Si et al. 2007; Silveri et al. 
2006; Volinia et al. 2006; Zhang et al. 2006; Zhu et al. 2007).  miR-21 consistently acts 
as an oncogene, and it is known to target the tumor suppressors: TPM1 (Tropomyosin 1) 
in breast cancer (Zhu et al. 2007) and PTEN in hepatocellular carcinomas (Meng et al. 
2007).  Recent work has also linked genes involved in p53’s pathway (PDCD4, CDK6, 
and Cofilin2) to increased miR-21 expression (Frankel et al. 2007).   
Simple expression studies are not the only investigations into miRNAs role in 
breast cancer.  Epigenetic studies have also revealed interesting methods of regulation.  
71 breast cancer specimens were analyzed and revealed a subset of miRNAs that 
undergo hypermethylation (Lehmann et al. 2007).  In particular, miR-9-1 was found to 
be differentially hypermethylated in normal breast tissue and demethylated in cancerous 
samples (Lehmann et al. 2007).  Additional studies are of course on-going and 
expanding every day, and this short review only covers the published data and is 
summarized in Table 4.  The obvious role the miRNAs have in breast cancer has sparked 
projects across the country and across the globe.  By identifying particular miRNAs  
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Table 4. Oncomirs in Breast Cancer. 
 
Oncomir Role in Breast Cancer    Reference(s)* 
 
miR-9-1  hypermethylated in normal mammary tissue    1 
 
miR-10b  induced by Twist and targets HOXD10, a repressor of RHOC   2,3,4  
  downregulted in tumors (microarray); associated with invastion   
and metastatsis; associated with ErbB2 status 
 
miR-15a  regulates BCL2 expression; copy number decreased in        5,6 
miR-16  breast tumors 
 
miR-17-92 cluster deleted in 21.9% of breast cancers    7 
 
miR-17-5p  tumor suppressor that targets AIB1 and E2F1; separate   8,9,10 
  reports show an upregulation in some breast cancers 
 
miR-21  oncogene; targets TPM1 and several components of the           2,4,6,7,10 
p53 pathway; higher expression in tumors    11,12,13,14 
 
miR-25  upregulateded in high grade tumors; associated with   4,6 
  ER/PR status       
 
miR-27a  oncogene; targets Myt-1 and Sp1, Sp2 and Sp3; histone is  15,16 
  acetylated 
 
miR-27b  tumor suppressor; targets CYP1B1; histone is acetylated   16,17 
 
miR-93  upregulated in high grade tumors     6 
 
miR-106b  upregulated in high grade tumors     6 
 
miR-125b  downregulated in tumor samples     2,4 
 
miR-142-5p associated with ER/PR status     4 
 
miR-145  downregulated in tumor samples     2,4 
 
miR-155  oncogene with differential expression between ER positive  4,6 
and negative tumors 
 
miR-200a  associated with ER/PR status     4 
 
miR-200c  targets TCF8 and therefore E-cadherin expression   18 
 
miR-205  associated with ER/PR status     4 
 
miR-206  regulates ERα      19 
 
let-7 family regulates ERα, RAS, and HMGA2; 7f is repressed in tumors   2,6,19 
  associated with ErbB2 status 
 
*References: 1:(Lehmann et al. 2007); 2: (Iorio et al. 2005); 3: (Ma et al. 2007); 4: (Mattie et al. 2006); 5: (Cimmino et al. 2005); 
6:(Blenkiron et al. 2007); 7: (Zhang et al. 2006); 8: (Hossain et al. 2006); 9: (O'Donnell et al. 2005); 10: (Lu et al. 2005); 11: (Zhu et 
al. 2007); 12: (Meng et al. 2007); 13: (Volinia et al. 2006); 14: (Frankel et al. 2007); 15: (Mertens-Talcott et al. 2007); 16: (Scott et 
al. 2006); 17: (Tsuchiya et al. 2006); 18: (Hurteau et al. 2007); 19: (Adams et al. 2007) 
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involved in cancer, a list of target miRNA genes is being generated for RNAinterference 
(RNAi) gene therapy. 
RNA Interference   
The discovery of the RNAi pathway by Fire and Mello (Fire et al. 1998), a Nobel 
Prize winning effort, has opened doors to new treatment options by silencing genes that 
cause diseases.  RNAi is an evolutionarily conserved process that leads to 
posttranscriptional suppression of gene expression.  Among other functions, it is thought 
to serve as a natural defense mechanism against a variety of pathogens including viruses 
(Lecellier et al. 2005).  Since the initial experiments in Caenorhabditis elegans which 
demonstrated sequence-specific gene silencing in response to double stranded RNA 
(Fire et al. 1998), numerous studies have been performed that clearly demonstrate RNAi 
is operational in most eukaryotic organisms.  These findings were the impetus for many 
subsequent scientific experiments carried out in recent years.  These investigations were 
directed towards characterizing RNAi machinery in various model organisms.   
 The use of RNAi as an experimental or therapeutic tool in mammalian systems 
was initially problematic.  However, approaches have been developed that avoid non-
specific dsRNA responses and permit the exploitation of RNAi for sequence-specific 
silencing in mammalian cells.  One such protocol involves the use of synthetically 
produced siRNAs of approximately 21 nucleotides in length that essentially mimic the 
cleavage products of Dicer.  These siRNAs, that we plan to employ in our research have 
been shown to be highly effective when transfected in mammalian cells to induce 
sequence-specific gene silencing. This makes siRNAs a powerful experimental tool for 
27 
 
probing gene function and expression (Elbashir et al. 2002).  Alternatively, synthetically 
created short hairpin RNAs (shRNAs) designed to target specific genes can also be 
transfected into cells and enter the RNAi pathway.  Both siRNAs and shRNAs are 
transient approaches, a more permanent option, would be to use actually incorporate a 
primary miRNA sequence into a cell’s genome using a virus.  Figure 2 summarizes the 
different approaches. 
 RNAi technology has rapidly become a molecular workhorse in functional 
genomic studies and is one of the most innovative approaches to studying gene function.  
Importantly, it is a new approach for the treatment and prevention of disease, and has 
emerged as the latest, most powerful technology in silencing expressed genes in 
eukaryotic organisms.  The precise action of the RNAi cellular machinery in silencing 
specific gene expression allows investigators to analyze gene function in vivo and in 
vitro in ways not previously possible.   
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Figure 2. Proposed mammalian RNAi pathway. Short hairpin RNAs (shRNAs) can be transfected into 
cells and enter the pathway by being recognized and processed by Dicer.  Once processed, a short 
interfering RNA (siRNA) is created and acts just like an endogenous miRNA in that one strand is 
incorporated into RISC and later binds to a target mRNA to repress translation.  This method is 
transient and dependent on the introduction of shRNAs into the system.  Consequently, a lasting gene 
therapy method relies on the incorporation of a pri-miRNA sequence into the actual nuclear genome 
or via a plasmid that is actively transcribed in the cell in order to be processed by Drosha. 
CYTOPLASM 
Imperfect pairing: 
Translational repression 
Perfect pairing: 
mRNA degradation 
shRNA siRNA 
Dicer 
Drosha 
Transcription 
Exogenous pri-miRNA sequence 
Figure 2. Proposed Mammalian RNAi Pathways. Short hairpin RNAs (shRNAs) can be 
transfected into cells and enter the pathway by being recognized and processed by Dicer.  Once 
processed, a short interfering RNA (siRNA) is created and acts just like an endogenous miRNA 
in that one strand is incorporated into RISC and later binds to a target mRNA to repress 
translation.  This method is transient and dependent on the introduction of shRNAs into the 
system.  Consequently, a lasting gene therapy method relies on the incorporation of a pri-
miRNA sequence into the actual nuclear genome or via a plasmid that is actively transcribed in 
the cell in order to b  processed by Drosha. 
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CHAPTER II 
MATERIALS AND METHODS 
 
 Canine miRNA Search 
All 447 human precursor sequences of the 9.0 Version of the Sanger miRNA 
Registry (http://microrna.sanger.ac.uk) were used to search for the homologous canine 
sequences using NCBI’s BLAST search program 
(http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=9615).  Identity 
percentage was calculated by dividing the number of matched bases by the total number 
of bases in the human precursor.  Mature percentages were calculated by dividing the 
number of matches at the mature sequence by the total number of bases in the mature 
sequence.  This search resulted in the identification of sixteen human precursor miRNA 
sequences (hsa-miR-17-3p, hsa-miR-17-5p, hsa-miR-18a, hsa-miR-19a, hsa-miR-19b, 
hsa-miR-20a, hsa-miR-92a, hsa-miR-15a, hsa-miR-16, hsa-miR-21, hsa-miR-29b, hsa-
miR-125b, hsa-miR-145, hsa-miR-155, hsa-miR-181b, and hsa-let-7f) that showed 
extreme sequence identity between the two genomes and which were selected for future 
study.  
 
RNA Isolation 
Tissue samples from the brain, heart, renal cortex, renal medulla, liver, and lung 
were collected from a mixed-breed, male dog and stored in RNAlater® (Ambion Inc., 
Austin, TX). Six primary canine mammary tumors were collected and used in this study.  
Tumor samples were stored in RNAlater. Ten normal mammary tissue samples were 
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collected from healthy adult female dogs that underwent an elective ovariohysterectomy 
(OHE) through Texas A&M University’s Veterinary Medical Teaching Hospital General 
Surgery Department with the proper permission from the university’s Clinical Research 
Review Committee.  At the conclusion of the OHE, a 1 centimeter incision was made 
over the most prominent mammary gland.  A sample of mammary tissue approximately 
3 mm x 10 mm was collected and stored in RNAlater® (Ambion Inc., Austin, TX).  
Procedures were all in compliance with TAMU’s CRRC #07-02.   
Total RNA was isolated from all samples using the mirVana miRNA Isolation 
Kit (Ambion Inc.) following the manufacturer’s recommended protocol. Samples were 
evaluated for quality and quantity using the NanoDrop
®
 ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE).   
 
Proof of Principle Experiments 
 TaqMan® MicroRNA Assays (hsa-miR-17-3p, hsa-miR17-5p, hsa-miR-18a, 
hsa-miR-19a, hsa-miR-19b, hsa-miR-20a, and hsa-miR-92a) were used to reverse 
transcribe seven mature miRNA molecules to cDNA (ABI).  For standard curve 
reactions, 300 ng, 30 ng, 3 ng, 0.3 ng, and 0.03 ng total lung RNA were used, and for all 
expression studies, 7 ng of RNA were used. Each 15 µl reverse transcription reaction 
contained: 5 µl of total RNA diluted to the appropriate concentration, 1X TaqMan® 
MicroRNA RT primer, 0.25 U RNase inhibitor, 1X RT buffer, 3.33 U MultiScribe™ 
reverse transcriptase, and 1 mM dNTPs (ABI).  The reverse transcription reactions were 
run in an Eppendorf MasterCycler (Westbury, NY) for 30 minutes at 16°C, 30 minutes 
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at 42°C, 5 minutes at 85°C, and then held at 4°C. Controls included reactions with no 
template, no primer, and the RNU6B TaqMan® Assay (ABI), which codes for a small 
RNA that has been validated by ABI as an appropriate control and confirmed for 
sequence identity in the canine genome.  
The reverse transcription products were diluted 1:15. The 20 µl real time reaction 
contained 1.33 µl diluted RT product, 1X TaqMan® Universal PCR Master Mix (No 
AmpErase® UNG), and 1X TaqMan® assay, which contained the forward and reverse 
primers as well as the TaqMan® probe. Each reaction was run in triplicate on a 96-well 
plate. Reactions containing no reverse transcription product served as negative controls.  
Reactions were incubated in an ABI7000 Prism Sequence Detection System for 10 
minutes at 95°C, followed by 40 cycles of 95°C for 15 seconds and 60°C for one minute. 
After completion of the qRT-PCR, the threshold value was manually set above 
the baseline displayed in the amplification plot.  Relative quantification of gene 
expression was evaluated by utilizing the comparative critical threshold (CT). The CT 
values for each mature miRNA reaction were subtracted from the respective CT value of 
the RNU6B control, resulting in the ∆CT value.  The largest ∆CT value was arbitrarily 
used as a constant that was subtracted from all other ∆CT values to determine ∆∆CT 
value.  Fold changes were then generated for each mature miRNA by calculating 2 -∆∆CT. 
The products from real time reactions were cloned and verified by sequencing.  
Real time products were cleaned using 0.05 U of shrimp alkaline phosphatase (Roche 
Applied Science, Indianapolis, IN) and 0.5 U of Exonuclease I (Epicentre 
Biotechnologies, Madison, WI) for a total reaction volume of 20 µl. Reactions were run 
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on an Eppendorf Mastercycler for 30 minutes at 37°C, 15 minutes at 80°C, and then held 
at 4°C. Products were cloned into TOPO4 vectors and sequenced through use of 
universal M13 primers. The Big Dye Termination Sequencing Kit (ABI) was used 
according to the manufacturer’s protocol. Sequencing was done using an ABI 3130 
Genetic Analyzer, and the resulting sequences were aligned to known target sequences 
using CLUSTAL W (http://www.ebi.ac.uk/clustalw/).  
 
Oncomir Experiments 
TaqMan® MicroRNA Assays (hsa-miR-15a, hsa-miR-16, hsa-miR-17-5p, hsa-
miR-21, hsa-miR-29b, hsa-miR-125b, hsa-miR-145, hsa-miR-155, hsa-miR-181b, and 
hsa-let-7f ) were used to reverse transcribe ten seven mature miRNA sequences to cDNA 
(ABI).  Each 15 µl reverse transcription reaction contained: 5 µl of total RNA diluted to 
a 1.4ng/µl concentration, 1X TaqMan® MicroRNA RT primer, 0.25 U RNase inhibitor, 
1X RT buffer, 3.33 U MultiScribe™ reverse transcriptase, and 1 mM dNTPs (ABI).  The 
reverse transcription reactions were run in a a BioRad thermocycler (Hercules, CA) for 
30 minutes at 16°C, 30 minutes at 42°C, 5 minutes at 85°C, and then held at 4°C. 
Controls included reactions with no template, no primer, and the RNU6B TaqMan® 
Assay (ABI), which codes for a small RNA that has been validated by ABI as an 
appropriate control.  
The reverse transcription products were diluted 1:15. The 20µl real time reaction 
contained 1.33 µl diluted RT product, 1X TaqMan® Universal PCR Master Mix (No 
AmpErase® UNG), and 1X TaqMan® assay, which contained the forward and reverse 
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primers as well as the TaqMan® probe. Each reaction was run in triplicate on a 96-well 
plate. Reactions containing no reverse transcription product served as negative controls.  
Reactions were incubated in an ABI7500 Prism Sequence Detection System for 10 
minutes at 95°C, followed by 40 cycles of 95°C for 15 seconds and 60°C for one minute. 
 After completion of the qRT-PCR, the threshold value was automatically 
configured above the baseline displayed in the amplification plot.  Relative 
quantification of gene expression was evaluated by utilizing the comparative critical 
threshold (CT). The CT values for each mature miRNA reaction were subtracted from the 
respective CT value of the RNU6B control, resulting in the ∆CT value.  The largest ∆CT 
value was arbitrarily used as a constant that was subtracted from all other ∆CT values to 
determine ∆∆CT value.  Fold changes were then generated for each mature miRNA by 
calculating 2 -∆∆CT.  Expression levels of normal samples were compared to cancerous 
samples using a standard MANOVA.    
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CHAPTER III 
PROOF OF PRINCIPLE EXPERIMENTS* 
 
Comparative Bioinformatics 
Countless investigations have used comparative genetics to elucidate orthologous 
genes.  Because of the conservation found between the canine and human genomes 
(Kirkness et al. 2003), it was hypothesized that miRNA genes were also conserved.  
Conserved miRNA genes have been found in as distantly related organisms as plants, 
worms and mammals (Tanzer and Stadler 2004), thus a high sequence identity was 
predicted for miRNA genes shared between the canine and human genomes.  The initial 
step for identification of canine miRNAs was a bioinformatics search that utilized the 
currently available genome sequence and the Sanger miRNA Database (Griffiths-Jones 
et al. 2006).  All human precursor sequences listed in the database were aligned with the 
domestic dog sequence using the BLAST application available on NCBI’s website 
(http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=9615).   
 Of the 447 human pre-miRNAs investigated, 268 were found to have a homolog 
in the canine genome.  Table 5 lists the breakdown of conservation found among the 
homologs.  289 mature miRNA sequences were located in the homolgous pre-miRNAs.  
When the mature sequences were analyzed for sequence identity, 265 were found to be  
____________________ 
*Reprinted in part from Gene 404, Boggs RM, Moody JA, Long CR, Tsai KL, Murphy 
KE, Identification, amplification and characterization of miR-17-92 from canine tissue, 
25-30, Copyright (2007), with permission from Elsevier. 
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completely conserved.  Since the mature miRNA segment is the functional element of 
the gene product that is responsible for binding to the target mRNA, it was expected to 
have a much higher conservation percentage, for it is much more intolerant of mutations.   
 
 
Table 5. DOGmi Data. Human precursor sequences were computationally compared to 
the canine genome sequences using the BLAST feature of the NCBI website. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 All of the data recorded from the in silico search was recorded in a database 
named DOGmi.  Human and canine chromosome locations are listed for each precursor 
available from the Sanger database Version 9.0, along with the percent of sequence 
Type of 
miRNA 
Canine/Human 
%Identity 
# of 
sequences 
Precursor 100 50 
 
95-99.9 135 
 
90-94.9 51 
 
<90 32 
   
Mature 100 265 
 
95-99.9 17 
 
90-94.9 4 
 
<90 3 
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identity, and the corresponding TaqMan® MicroRNA Assay that can be used to quantify 
the miRNA’s expression levels.   
A similar approach was undertaken by another laboratory.  In addition to 
sequence identity, a program called RNAZ was employed to analyze the RNA’s energy 
and structure.  Rat and mouse genomes were also used in addition to the canine and 
human genome for comparison.  The group established a publicly available database for 
their findings and refer to it as MiRMap. 
 
Introduction to the miR-17-92 Cluster 
miRNA genes are distributed throughout the genomes of both plants and animals.  
They are often found in clusters and are located in almost every region of the 
mammalian genome including introns, exons, and the 3′ UTR of genes. One specific 
cluster, miR-17-92, has been widely studied in the human and other organisms.  This 
cluster is evolutionarily conserved with homologs in Mus musculus, Rattus norvegicus, 
Canis familiaris, Xenopus tropicalis, Pan troglodytes, Takifugu rubripes, Tetraodon 
nigroviridis, and Danio rerio (Tanzer and Stadler 2004). One of the genes in the cluster, 
miR-92, even has homologs in the invertebrates C. elegans and Drosophila (Tanzer and 
Stadler 2004).  Aberrant expression of this cluster has also been studied in multiple 
organisms and linked to several cancers (Hayashita et al. 2005; He et al. 2005; Hossain 
et al. 2006). 
The purpose of the work reported herein was to (1) validate the use of Applied 
Biosystems Inc.’s (ABI’s) TaqMan® MicroRNA Assays (Foster City, CA), originally 
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designed for human miRNAs, as a tool to study canine miRNA expression and (2) verify 
the expression of miRNA genes in canine tissues.  To this end, human miRNA precursor 
sequences were used to identify putative canine miRNA genes by sequence identity. 
TaqMan® Assays were validated for use with canine miRNAs and expression of the 
canine miR-17-92 cluster was evaluated in six different canine tissues of a normal 
mixed-breed dog. 
 
Results and Discussion 
Identification 
According to the 9.1 version of the Sanger miRNA Registry, only six miRNAs 
have been identified in the canine genome (Griffiths-Jones et al. 2006; Xie et al. 2005).  
These canine miRNAs were identified through a computational search and have not been 
experimentally confirmed (Xie et al. 2005). As such, this study is the first to evaluate 
expression of miRNAs from canine tissues.  Other investigations have characterized 
miRNA expression in the human, mouse, and pig (Chen et al. 2005; Fu et al. 2005; 
Hayashita et al. 2005; Lagos-Quintana et al. 2001; Lagos-Quintana et al. 2002; Sawera 
et al. 2005; Sempere et al. 2004).  By identifying and validating a tool to study miRNA 
expression in the dog, both species-specific and comparative genomic data were 
obtained. 
In order to study canine miRNA expression, identification of putative miRNA 
sequences was necessary.  The miR-17-92 cluster has been characterized in vertebrates 
as well as invertebrates (Calin et al. 2004b; Houbaviy et al. 2005; Sawera et al. 2005; 
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Tanzer and Stadler 2004). Importantly, genes within the miR-17-92 cluster are associated 
with various human cancers which may be modeled in the domestic dog (Esquela-
Kerscher and Slack 2006; Hayashita et al. 2005; He et al. 2005; Hossain et al. 2006; 
Hwang and Mendell 2006; Thomson et al. 2006).  For these reasons, the canine miR-17-
92 cluster was chosen for this investigation. The human miR-17-92 precursor sequences 
(hsa-miR-17-3p, hsa-miR-17-5p, hsa-miR-18a, hsa-miR-19a, hsa-miR-19b, hsa-miR-
20a, and hsa-miR-92a) were used to search for the corresponding canine precursors. The 
miR-17-92 cluster, located on human autosome 13, showed perfect sequence identity to a 
region on canine autosome 22.  The extent of conservation between the human and the 
dog, as well as the presence of these genes in numerous other species, strongly suggests 
functional importance for this cluster of miRNA genes. 
Amplification and Validation of Canine miRNAs 
Of the various tools available to study miRNA expression, the TaqMan® 
MicroRNA assay (detailed in Figure 3) was chosen over northern blotting and 
alternative real time approaches for several reasons. Each TaqMan® assay uses primers 
and a fluorescent probe that are specific for a single, mature miRNA sequence. These 
primers are unique in that they are looped and are able to differentiate between mature 
miRNA sequences that may differ by only a single nucleotide. Also, this assay is 
specific for mature rather than pre-miRNA molecules. This is important because pre-
miRNA expression levels do not always coincide with mature miRNA levels (Sawera et 
al. 2005). Because miRNAs are only functional at the mature stage, quantification of 
expression levels of mature miRNAs is preferred over pre-miRNAs. TaqMan® assays  
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Figure 3. Stem-loop RT-PCR.  TaqMan® MicroRNA Assays used novel stem-loop 
primers designed by Applied Biosystems for the amplification of hundreds of miRNAs 
from several species.  The assays utilized the pathway shown above in order to amplify 
only the mature miRNA products with a probe specific enough to differentiate miRNAs 
that may only differ by one nucleotide (Chen et al. 2005).   
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also use qRT-PCR. Real time experiments require less RNA input than traditional 
northern blots, and they can detect RNA transcripts present at extremely low levels. The 
specificity and sensitivity of this approach made it the ideal candidate for investigation 
of canine miRNA expression. Validation of the TaqMan® assays for use with the canine 
system was necessary before relative expression levels could be determined. 
Dilution curves with canine RNA were used to determine the specificity and 
sensitivity of the miRNA assays originally designed for the human.  Each primer and 
probe set for the miR-17-92 cluster and the RNU6B small RNA were tested with total 
RNA isolated from canine lung.  The RNA input ranged five logs (300 ng-0.03 ng).  
Data showed that the critical threshold (CT) value decreased as the amount of RNA input 
increased, which is expected for primer and probe assays that are sensitive. The graph 
depicted in Figure 4 demonstrates that the relationship between RNA input and CT is 
linear and direct.  Table 6 compares the correlation values (R
2
) of each assay over four 
and five orders of magnitude.  While some sensitivity was lost when 300 ng of RNA 
were used, correlation values still remained close to one, thereby confirming the 
sensitivity of the assays’ ability to quantify canine miRNA expression over a dynamic 
range of RNA input. Real time products from all seven genes and the control were 
subcloned and verified by sequencing. Taken together, these data indicate that the 
TaqMan® assay is suitable for investigation of canine miRNA expression. 
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Figure 4. Standard Dilution Curves. Human TaqMan® miRNA assays were validated for 
sensitivity using canine RNA. 
 
 
 
 
Table 6.  Correlation Values for the miR-17-92 Cluster. 
 
 
R2 values 
4 orders of magnitude 
(0.03ng-30ng) 
R2 values 
5 orders of magnitude 
(0.03ng-300ng) 
RNU6B control 
0.9797 0.8882 
miR-17-3p 0.9979 0.9442 
miR-17-5p 0.9845 0.9746 
miR-18 0.9954 0.9390 
miR-19a 0.9927 0.9415 
miR-19b 0.9907 0.9859 
miR-20 0.9870 0.9935 
miR-92 0.9996 0.9943 
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Quantification of miRNA Expression 
Having validated use of the miRNA TaqMan® assays, a tissue-specific 
evaluation of the expression of the miR-17-92 cluster was performed using canine heart, 
brain, lung, liver, renal cortex, and renal medulla tissues. In addition to confirming the 
presence of individual miRNAs, the real time approach proved quite suitable for 
quantifying the relative expression levels of miR-17-92. These data are displayed in 
Figure 5.   
The overall expression of canine miR-17-3p and 17-5p is relatively low as 
compared to other genes in this cluster.  For these genes, the highest expression was in 
the renal medulla and the lowest expression in the liver.  Because the levels of mature 
miRs-17-3p and 17-5p are relatively low in mammalian tissues, they are often unable to 
be quantified by northern blotting (Hayashita et al. 2005; Sawera et al. 2005); however, 
the presence of miR-17-5p has been detected in murine lung, brain, heart, and kidney 
using cloning techniques (Sempere et al. 2004).  The previous difficulties in studying 
expression of these two genes highlight the need for a better detection method. 
Therefore, the real time approach used in this study will be a useful tool in subsequent 
investigations.  
The highest relative expression of canine miR-18 was in the renal cortex, 
followed by the lung. Expression was negligible for other tissues analyzed.  Likewise, 
the murine form of miR-18 has been detected in both lung and total kidney (Sempere et 
al. 2004).  In addition, northern blotting revealed expression of miR-18 in porcine kidney 
and brain (Sawera et al. 2005). 
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Figure 5. miR-17-92 Expression. Canine expression of the cluster was quantified in six 
tissues (brain, heart, lung, liver, kidney cortex, and kidney medulla) using qRT-PCR.  
Expression of the seven miRNAs in the miR-17-92 cluster were individually analyzed 
using the delta, delta Ct method of comparison.    
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The profiles of miRs-19a and 19b followed the same general trends when 
compared among the six canine tissues:  the highest and lowest relative expression levels 
were found in the heart and liver, respectively. Previous experiments done using 
northern blotting were unable to distinguish between mirs-19a and 19b, because the 
mature sequences differ by a single nucleotide (Lagos-Quintana et al. 2001). The real 
time primers and probes used in the current experiments allowed discrimination between 
the two miRNAs as demonstrated by sequencing. Although northern blotting cannot 
differentiate between the two genes, mir-19a has been cloned from murine lung as well 
as the human brain, heart, and liver (Sempere et al. 2004).  In addition, miR-19b was 
cloned from murine lung, brain, liver, heart, and kidney (Sempere et al. 2004). 
The expression of canine miR-20 is highest in the heart and lowest in the liver as 
compared to the other tissue samples. Overall, the trend was heart > renal cortex > brain 
> lung/renal > medulla > liver. A murine expression profile of mir-20 has been 
previously generated by use of TaqMan® real time assays. Chen and colleagues (2005) 
demonstrated that mir-20 mature expression was highest in the lung, followed by the 
heart, liver, and brain (the kidney was not studied). Although a quantitative approach 
was taken by them and also in the work reported here, it is difficult to make comparisons 
between the dog and mouse due to the limited number of samples used in both studies. 
Detection of miR-20 has also been reported from human lung and murine kidney and 
lung (Sempere et al. 2004).   
Overall expression of canine miR-92 was very dynamic with relative fold 
changes ranging from 10 to over 200, as seen in the liver and heart, respectively. 
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Although northern blotting is not the ideal method to quantify expression levels, Sawera 
et al. showed that the mature form of porcine miR-92 is highly expressed in the liver as 
compared to the kidney and brain.  Work with murine lung, heart, and kidney was able 
to produce clones of this gene (Sempere et al. 2004).   
 
Conclusions 
It is interesting to note that reports assessing renal miRNAs identified the tissue 
of origin as “kidney” but did not indicate whether the sample was from the renal medulla 
or the renal cortex.  The work reported here shows that within an organ, such as the 
kidney, the miRNA expression profiles do differ among the different cell populations.  
Therefore, because other reports do not identify the cellular origins of samples, direct 
conclusions and comparisons cannot be made.   
Provided here is a summary of data collected for different species with regards to 
the mir-17-92 cluster. These data cannot be directly compared among species because of 
differences in techniques and the limited number of samples used. Comparing 
expression levels of individual miRNAs across species will allow for identification of 
species-specific differences and, perhaps, provide insight into miRNA function at the 
comparative genomic level. As additional data is published using the real time approach, 
making these comparisons will be possible. 
We have shown the sensitivity and specificity of TaqMan® assays using canine 
samples, thereby validating use of this approach.  Initial expression profiles of the mir-
17-92 cluster were generated for several canine tissues. As previously mentioned, six 
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canine miRNAs have been identified through computational methods; however, this is 
the first study to demonstrate that canine miRNAs are actually expressed. It is important 
to note that, although initial observations regarding relative expression levels were made, 
more samples from a number of different dogs must be included to create true baseline 
profiles for normal expression. The establishment of a tool to study miRNA expression 
in the canine system will also allow for future expression studies to evaluate miRNA 
genes that have been associated with cancer and other diseases. 
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CHAPTER IV 
 
CANINE MAMMARY ONCOMIR STUDY 
 
Introduction 
 The domestic dog may provide the ideal model for oncomir research.  Due to the 
fact that mammary cancer is a spontaneously occurring disease in the domestic dog (as 
opposed to the often used induced rodent models or manipulated in vitro models), the 
functional genetics can be more accurately explored.  The genetic similarities found 
between the two species could also mean a conservation of function in that miRNAs 
may be targeting genes conserved between the human and canine genomes to initiate 
tumorigenesis or progress metastasis.  Previous researchers have shown links between 
ten miRNAs and breast cancer (summarized in Table 7).  This study takes the first step 
in the canine avenue by identifying the expression levels of oncomirs in canine 
mammary cancer using the highly sensitive qRT-PCR approach.   
 
Results 
 Bioinformatic data revealed the ten oncomirs of interest (miR-15a, miR-16, miR-
17-5p, miR-21, miR-29b, miR-125b, miR-145, miR-155, miR-181b, let-7f) to have 
substantial sequence identity between the human and dog at the precursor level and 
complete conservation at the mature level.  Sequence identity is detailed in Table 8.  
Based upon previous research, the identity found at the mature level permits the use of 
the ABI TaqMan® MicroRNA assays with canine input despite being designed for the  
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Table 7. miRNA Research in Mammary Cancer. 
______________________________________________________________________________________________ 
miRNA name Human   Cancer Source         Function     Analysis Method         References* 
______________________________________________________________________________________________ 
 
miR-15a  13q14  Primary tumors        Tumor           Microarray         1,2,3 
  (intron 4 of Cell lines                Suppressor          aCGH   
  DLEU2) 
 
miR-16  13q14  Primary tumors        Tumor           Microarray         1,2,3 
  (intron 4 of Cell lines                Suppressor          aCGH   
  DLEU2) 
 
miR-17-5p 13q31  Primary tumors        Tumor           Microarray      1,2,3,4,5 
  (intron 3 of Cell lines                Suppressor/           aCGH  
  C13orf25)          Oncogene 
 
miR-21  7q23  Primary tumors        Oncogene          Microarray  2,3,5,6 
  (3’UTR   Cell lines                             Northern Blotting  
  VMP1)               aCGH                          
 
miR-29b  7q32 &  Primary tumors        Oncogene          Microarray  2,3,5 
  1q32  Cell lines             aCGH                       
  (intergenic) 
   
miR-125b 11q24   Primary tumors        Tumor           Microarray       2,3,7 
  (intergenic) Cell lines         Suppressor          Northern Blotting  
  & 21q1 (intron              aCGH            
  of C21orf34) 
 
miR-145  5q32  Primary tumors        Tumor           Microarray  2 
  (intergenic) Cell lines         Suppressor          Northern Blotting 
 
miR-155  21q21.3  Primary tumors        Oncogene          Microarray  2,5 
  (exon 3 of Cell lines 
  ncRNA BIC) 
 
miR-181b 9q33.3  Primary tumors        Tumor           Microarray  3,5 
  (intergenic)          Suppressor/          aCGH 
             Oncogene 
 
let-7f  Several  Primary tumors        Tumor           Microarray       2,6,7 
  sites  Cell lines         Suppressor          qRT-PCR   
______________________________________________________________________________________________ 
*References: 1: (Calin and Croce 2006b); 2: (Iorio et al. 2005); 3: (Zhang et al. 2006); 4: (Hossain et al. 2006); 5: 
(Volinia et al. 2006); 6: (Jiang et al. 2005); 7: (Mattie et al. 2006) 
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corresponding miRNA genes of the human (Boggs et al. 2007).  qRT-PCR was chosen 
as the method of choice to quantify miRNA expression due to its need for very little 
RNA input as well as the specificity and sensitivity of TaqMan®.   
 
 
Table 8. Mammary Oncomir Conservation Comparison. 
 
 
A brief comparison (see Figure 6) of the overall expression of the ten miRNAs 
studied with qRT-PCR and analyzed with the traditional delta, delta Ct method, reveals 
five miRNAs with tumor suppressor activities (miRs-15a, 16, 17-5p, 125b and 155) and 
four with oncogenic activity (miRs-21, 29b, 181b, and let-7f).  MiR-145 does not seem to 
differ in expression between normal and malignant mammary tissues.  The statistical 
analysis to compute p-values (listed in Table 9) was performed using the Multivariate 
Analysis of Variance (MANOVA) calculation, a more robust test than the standard t-
test. MANOVA takes into account that all ten miRNAs were evaluated on the same six 
samples, and it revealed miR-21 and miR-29b to be significantly different (p.05).   
miRNA Human 
location 
Canine 
location 
Precursor 
Identity (%) 
Mature 
Identity (%) 
let-7f 9/X 1/X 100 100 
miR-15a 13 22 100 100 
miR-16 13 22 97.5 100 
miR-17-5p 13 22 100 100 
miR-21 17 9 99 100 
miR-29b 7/1 14/7 100 100 
miR-125b 11 5 98 100 
miR-145 5 4 94 100 
miR-155 21 31 94.5 100 
miR-181b 1 7 95.5 100 
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Figure 6. Mammary Oncomir Expression.  Expression levels of 10 oncomirs were 
studied from normal and cancerous canine breast tissue and compared using a 
MANOVA analysis. A. Compares all six tumor samples versus ten normal samples.  B. 
Compares two tubular papillary carcinoma samples to the ten normals.  C. Compares 
three ductal carcinoma samples to the ten normal samples.   
  
Normal Cancer 
A 
B 
C 
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Table 9.  P-values for Total and Subtype Analysis. P-values are listed for each miRNA 
and were calculated using MANOVA. 
 
Normal Mammary Tissue vs. All Cancer Samples 
 
miR 15a 0.09 
miR 16  0.16 
miR 17-5p  0.34 
miR 21   0.01* 
miR 29b 0.05* 
miR 125b  0.46 
miR 145  0.99 
miR 155  0.48 
miR 181b  0.23 
let-7f  0.30 
 
Normal Mammary Tissue vs. Ductal Carcinomas 
 
miR 15a 0.98 
miR 16  0.19 
miR 17-5p  0.61 
miR 21   0.000019* 
miR 29b 0.003* 
miR 125b  0.36 
miR 145  0.59 
miR 155  0.38 
miR 181b  0.002* 
let-7f  0.002* 
 
Normal Mammary Tissue vs. Tubular Papillary Carcinomas 
 
miR 15a 0.024* 
miR 16  0.009* 
miR 17-5p  0.145 
miR 21   0.158 
miR 29b 0.492 
miR 125b  0.154 
miR 145  0.504 
miR 155  0.129 
miR 181b  0.977 
let-7f  0.337 
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However, the biological trends cannot be ignored and will be further addressed in the 
discussion.   
 Further analysis compared the samples based upon two types of histology (ductal 
carcinomas and tubular papillary carcinomas) revealing miR-15b and miR-16 to have a 
significantly lower expression in canine ductal carcinoma diagnoses versus normal 
samples. The ductal carcinomas were identified by neoplastic cells invading the 
mammary gland.  Alternatively, tubular papillary carcinomas invaded the mammary 
glands, producing abnormal tubular projections into the duct.  The tubular papillary 
tumors had a higher expression of let-7f and miR-181.  This is in addition to miR-21 and 
miR-29b, and indicates that these four genes may have oncogenic roles in this particular 
type of malignancy.   
 
Discussion 
 It was not surprising to find the oncomirs of interest are highly conserved 
between the canine and human.  Previous analysis of the two species has revealed that 
the canine sequence, as a whole, shows great sequence identity to the human, even more 
than the popular murine model (Kirkness et al. 2003). The physiology of the dog enables 
larger and easier to obtain specimen collections as compared to rodent models.  The 
companion animals also have extraordinary health care, second only to that of the human 
medicine. The vast similarities in both genetics and physiology and considerable overlap 
in treatment regimens make the domestic dog an ideal model for many human diseases, 
including malignant mammary cancer.   
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 Like the human, the domestic dog is known to have several risk factors for the 
development of mammary cancer.  All canine mammary tumors appear to be promoted 
by sex hormones (Lana et al. 2007).   Studies have shown that there is a direct 
correlation between the total amount of estrogen exposure and the risk for mammary 
tumor development.  Dogs that are spayed before their first, second, or third estrus cycle 
have a risk of 0.5%, 8%, and 26% respectively for developing a mammary 
tumor(Schneider et al. 1969).  This is similar to human research that has shown that 
early aged menopausal women have a significant decrease in risk for development of 
mammary cancer compared to those women who reach menopause at biologically 
normal times (Dickson et al. 2005). 
 It must be noted that what is known about the role of estrogen receptors in canine 
mammary tumors indicates that they may not be good biologic models of human 
mammary cancer.  That is, while estrogen clearly promotes the growth of breast cancer 
in both species (Dickson et al. 2005; Schneider et al. 1969), multiple studies have shown 
that in true canine mammary malignancies, estrogen receptors are down-regulated 
compared to normal mammary tissue (Illera et al. 2006; Millanta et al. 2005; Nieto et al. 
2000).  This finding is markedly different when compared to the majority of human post 
menopausal mammary cancer (Dickson et al. 2005). Consequently, estrogen receptors 
blockers such as tamoxifen have little effect in the dog.  Interestingly, dysplasia and 
benign canine tumors have elevations in the estrogen receptors similar to women.  Thus, 
the potential of dogs with mammary tumors to serve as models for study of human 
mammary cancers is not without complication.  Even so, the conflicting data pertaining 
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to estrogen receptors is outweighed by the aforementioned shared characteristics 
between canine and human mammary cancers.  These similarities suggest that while 
treatment response may vary due to the lack of estrogen receptors, the biologic 
development and progression of mammary cancers in these two species is similar 
enough to enhance the understanding of human mammary cancer through the use of the 
canine model.  To this end, evaluation of miRNAs in canine mammary tissue may be a 
highly productive avenue of investigation. 
 Previous work grouped oncomirs into three categories: tumor suppressors, 
oncogenes, and those that fulfill both functions (Calin and Croce 2006a; Esquela-
Kerscher and Slack 2006; Wijnhoven et al. 2007; Zhang et al. 2007).  Because miRNAs 
can bind to more than one mRNA (see Figure 2), it is not only possible, but more than 
likely, that they will bind to several mRNAs.  Likewise, the miRNAs studied in this 
manuscript can be placed into one of the three categories.   
Tumor Suppressors 
 The first oncomirs, miRs-15a and 16, were initially discovered to play a role in 
chronic B-cell lymphocytic leukemia (Calin et al. 2004a). They are clustered together at 
a known cancer fragile site and act to suppress tumors by reppressing BCL2, an anti-
apoptotic oncogene (Cimmino et al. 2005).  The loss of these two miRNAs results in 
overexpression of BCL2 and subsequent pro-survival states, a documented event in the 
majority of chronic cases of B-cell lymphocytic leukemia cases (Cimmino et al. 2005).  
Decreased expression and a loss in copy number of miR-15a and miR-16 were found in 
other hematopoetic and solid cancers, including human mammary cancers (Bottoni et al. 
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2005; Iorio et al. 2005; Mattie et al. 2006; Volinia et al. 2006).  The work reported here 
provides evidence that both miR-15a and miR-16 are generally suppressed in canine 
mammary carcinomas.  However, when the ductal carcinoma phenotype is singled out, 
the different patterns of expression become significant.  It is thus reasonable to 
hypothesize that miR-15a and miR-16 may be responsible for the differentiation of the 
malignancy.   
 Another known tumor suppressor, miR-125b, also acts to control cell 
proliferation, and regulates the oncogene Lin28 in the human (Lee et al. 2005; Wu and 
Belasco 2005). Expression of this miRNA in the dog is reduced in malignant samples as 
compared to normal mammary tissues.  This is in agreement with microarray, northern 
blotting and comparative genomic hybridization studies done on primary and in vitro 
samples from the human (Blenkiron et al. 2007; Iorio et al. 2005; Mattie et al. 2006; 
Volinia et al. 2006; Zhang et al. 2006). 
 Differential expression of miR-145 was not detected in canine mammary cancer, 
but it is described as a tumor suppressor and has been found to target FLJ21308 in the 
human (Kiriakidou et al. 2004).  This oncomir is more often associated with colorectal 
tumors (Bandres et al. 2006), but studies have documented a differential expression in 
mammary cancer (Iorio et al. 2005; Volinia et al. 2006).  It is interesting to note that one 
group described the expression of both the mature and precursor expression levels of 
miR-145 in colorectal tumors, but only found a difference at the mature level (Michael et 
al. 2003).  This finding underscores the importance of choosing expression tools that 
target the “functional element” of miRNAs, i.e. the mature product. 
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Oncogenes 
 The oncogenes, miR-21 and miR-29b are associated with numerous cancers, 
including human mammary cancer (Blenkiron et al. 2007; Esquela-Kerscher and Slack 
2006; Fabbri et al. 2007; Frankel et al. 2007; Iorio et al. 2005; Mattie et al. 2006; Meng 
et al. 2007; Mott et al. 2007; Pekarsky et al. 2006; Si et al. 2007; Silveri et al. 2006; 
Volinia et al. 2006; Zhang et al. 2006; Zhu et al. 2007). Consistently, these two miRNAs 
are up-regulated in analyses of mammary cancers using microarrays, and Zhang and 
colleagues confirmed that these two oncogenes showed an increase in copy number in 
mammary tumor tissues (2006).  In particular, miR-21 targets both PTEN and TPM1, and 
the loss of this miRNA results in increased caspase activity and subsequent apoptosis 
(Meng et al. 2007; Zhu et al. 2007).  Tcl1 and MCL1 are targets of miR-29b (Mott et al. 
2007; Pekarsky et al. 2006). Because these miRNAs have roles in so many cancers, it is 
reasonable to hypothesize that they have a role in general role in tumorigenesis rather 
than a specific role in metastasis or development of mammary cancers.  Both miRNAs 
were significantly up-regulated in tumors for this study (p.05).  They remained 
significant even when the tubular papillary carcinoma phenotype was separately 
analyzed.  Because of the increased expression, miR-21 and miR-29b may be ideal 
targets for in vitro knockdown studies.  By targeting the supposed oncogenic activity, 
perhaps tumor growth could be slowed or halted altogether. 
Combination Tumor Suppressors and Oncogenes 
 Some miRNAs serve opposing roles, specifically as both tumor suppressor and 
oncogenes.  This is the most interesting and complicated category of miRNAs, and as 
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functional studies continue and more data are generated, it is likely that many more 
oncomirs will be found to have these dual roles. 
 Known to suppress the oncogene AIB1, miR-17-5p would be classified in the 
tumor suppressor category (Hossain et al. 2006).  However, it is also known to target 
E2F1, the transcription factor for c-Myc (Hossain et al. 2006; O'Donnell et al. 2005). 
Previous work showed overexpression of miR-17-5p in several cancers, and this miRNA 
is known to specifically accelerate C-MYC-induced tumorigenesis in the mouse (He et 
al. 2005).  Both Iorio et.al. (2005) and Volina et.al. (2006) used microarray data to 
suggest that miR-17-5p acts as an oncogene in mammary cancers while multiple other 
studies used a variety of techniques to show evidence of miR-17-5p acting as tumor 
suppressor (Hossain et al. 2006; Lu et al. 2005; O'Donnell et al. 2005; Zhang et al. 
2006). In fact, this miRNA is deleted, due to its fragile site position, in 21.9% of breast 
cancer samples (Zhang et al. 2006).  The data from the dog correlate with the majority of 
the findings when all mammary tumors and when tubular papillary carcinomas were 
analyzed.  There does not seem to be a difference in expression in the ductal carcinomas.  
Because the differences were not statistically significant, additional tumor samples 
would need to be collected to further investigate the role of miR-17-5p in canine 
mammary cancer. 
 In chronic lymphocytic leukemia, miR-181b targets Tcl1, another known 
oncogene, suggesting that the miRNA is a tumor suppressor (Pekarsky et al. 2006).  
Other work implicated the gene in differentiation of B-cells (Chen and Lodish 2005).  In 
human glioblastoma and pituitary adenomas, miR-181b seems to act in a tumor 
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suppression fashion (Bottoni et al. 2007; Ciafre et al. 2005).    However, Zhang et.al. 
(2006) convincingly reported an increased copy number of miR-181b in mammary 
tumors, and microarray studies showed overexpression of this miRNA in mammary 
cancer tissue samples (2006).  Overall, the canine mammary tumors appear to over 
express miR-181b.  In the tubular papillary carcinomas, the miRNA is significantly 
overexpressed, indicating that miR-181b may be an important in differentiation of 
mammary cells as well. 
 Located within the BIC gene, miR-155 is generally thought of as an oncogene, 
because it is overexpressed in heamopoeitic cancers, thyroid cancers and lung 
adenocarcinomas (Costinean et al. 2006; Mattie et al. 2006; Volinia et al. 2006; Zhang et 
al. 2006). Microarray data showed an increase in expression in multiple tumor samples 
of different origins giving further evidence for this oncogenic role (Iorio et al. 2005; 
Volinia et al. 2006).  However, a study on pancreatic cancer showed miR-155 to be 
down-regulated (Roldo et al. 2006).  In canine mammary cancers, the miRNA takes on 
both roles, dependent upon tumor differentiation.  The average expression in tubular 
papillary carcinomas is lower compared to normal mammary tissue, while the ductal 
carcinomas display a slightly higher expression when compared to the healthy 
counterparts.  It is important to note that only the averages are being compared, because 
the difference of expression was not considered statistically significant. Interestingly, 
Mattie and colleagues found that miR-155 is differentially expressed when comparing 
estrogen receptor positive and negative tumors (2006).  
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 A part of the let-7 family of miRNAs, let-7f is described as a tumor suppressor 
because it knocks down the oncogene, ras (Johnson et al. 2005).  The let-7f miRNA is 
conserved in as distantly related species as the worm, plant, and fruitfly (Pasquinelli et 
al. 2000).  By targeting K-ras and N-ras mRNA for degradation, let-7f’s role in cancer 
cell proliferation was clear (Johnson et al. 2007). In addition, multiple studies have 
shown a reduced expression of this miRNA in lung cancer (Jiang et al. 2005; Johnson et 
al. 2007; Johnson et al. 2005).  However, one study used the highly sensitive qRT-PCR 
and showed an up- regulation of let-7f in breast cancer cell lines (Jiang et al. 2005).  
Only the tubular papillary carcinomas of canine mammary cancer showed a statistically 
significant increase in expression of let-7f, and supports the findings of the qRT-PCR 
study.   
 The data collected in this study were generated using a qRT-PCR approach that 
has proven specificity and sensitivity. This technique is vital when there is very little 
RNA obtained from the mammary biopsies and the miRNAs being quantified only differ 
by one nucleotide.  While northern blots were not performed to confirm the data, 
previous research has shown the qRT-PCR approach to be more accurate.  In addition, 
the RNU6B assay was chosen as the “housekeeping gene” for two reasons:  previous 
researchers have used the U6 control, making the data comparable, and the expression of 
RNU6B was found to be relatively consisted among several cancers (Jiang et al. 2005). 
 Relatively few samples were used in this study due to the difficulty in obtaining 
tumor and normal tissue from client owned animals.  This means that while most of the 
miRNAs did not show statistically significant differences, they still may play vital roles 
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in cancer.  The analysis of more tumor samples to improve the power of the study is 
required before any definitive statements on the role of miRNAs in canine mammary 
cancer are made.  This point underscores the need for future collaborations between 
veterinarians and researchers as well as the establishment of tumor banks. 
 The fact that the domestic dog appears shares characteristics with human breast 
cancers as described in copious literature is encouraging as it provides theory for future 
research that utilizes the dog as a breast cancer model.  As more samples are collected 
and in vitro cell lines are established, more canine phenotypes can be explored and 
compared to the human forms of malignancy beyond just breast cancer.  The cell type 
specific actions should be further investigated and predicted targets can be tested in cell 
lines derived from canine tumor samples.  Elucidating the actions of miRNAs will 
advance cancer diagnostics, treatment and survival by providing gene therapy targets of 
the future. Ideally, the miRNAs found to be involved in tumorigenesis or tumor 
suppression could serve as targets for gene therapy in both the dog and the human. 
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CHAPTER V 
CONCLUSIONS AND FUTURE STUDIES 
 
The National Institute of Health is now recognizing how valuable comparative 
studies are by forming the Comparative Oncology Trials Consortia, COTC, which, 
through14 veterinary schools, perform clinical trials on dogs and cats with cancer.  With 
increased acceptance by researchers, the domestic dog could provide great insight into 
the future on human breast cancer cures.  But the benefit directly to veterinary studies 
cannot be overlooked.  Finding effective treatments for pets suffering from breast cancer 
could alleviate much pain and cost to today’s pet owners, many of which consider their 
dog a true member of their family. 
 
Summary 
By showing the expression of miRNAs in the dog and specifically in canine 
mammary cancer, the first steps of canine oncomir research have been set forth.  A 
comparative in silico analysis has been completed identifying close to 300 miRNAs that 
are conserved between the canine and human genomes.  The miR-17-92 cluster and nine 
additional oncomirs have been investigated by using a verified and sensitive quantifiable 
approach.  The resulting data show that canine miRNA expression is similar to that of 
the human.  Expression is tissue specific, and different subtypes of mammary cancer 
(tubular papillary carcinomas and ductal carcinomas) show different expression profiles.   
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Conclusions and Future Directions 
Simply put, the domestic dog may be an excellent model for the study of human 
miRNA studies.  Research is this field will advance both human and veterinary 
medicine.  Although evaluated in a small number of samples, two oncomirs, miR-21 and 
miR-29b, show very significant differences in expression, and both act as oncogenes.  
These two have also been investigated in the mouse, rat, and human and have been 
found to act as oncogenes in those species as well.  Their high conservation may lead to 
a therapeutic target for multiple species.  Additional samples and future research could 
identify other targets. 
  Ideally, canine specific miRNAs could be cloned and sequenced.  A microarray 
analysis could be done on the human miRNA chip that may reveal differences between 
the canine mammary tumors and normal mammary tissue.  With more tumor samples, 
more robust statistical analysis could be used.  Immunochemistry and protein analyses 
could be initiated to differentiate the subtypes and complement the genetic discoveries.  
When the tumors are separate by subtypes, profiles can be made like they were in the 
human.  By understanding the profiles we can not only target our veterinary treatments, 
but also effectively separate the different functional mechanisms that are in place.  Now 
we must dive into the world of canine oncomirs and investigate what their functional 
roles are and if the roles are conserved in the human as well.   
One approach would be to use the targets of these particular miRNAs and 
compare the targets between humans and dogs.  It follows that if the miRNAs function 
the same in both species they may be targeting the same mRNAs, so these homologous 
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mRNAs will probably be highly conserved between species.  Ultimately, knockdown 
and knock-in experiments will need to be performed by using shRNAs and antigomirs to 
manipulate a specific miRNA. Thus canine normal and tumor mammary cell lines will 
need to be created from primary tissue in order to evaluate and study miRNAs at work in 
the canine in vitro model. 
The end goal of this research will always be: finding a cure.  Genetically 
modified viruses can be used with in vivo models for gene therapy.  Clinical trials could 
use a therapeutic virus to manipulate the expression of a specific miRNA or multiple 
miRNAs to control or reduce tumor growth.  If successful in the dog, the virus could be 
modified and further tested in the human.  In addition, human RNAi trials are currently 
being investigated.  If success is found in the human area, the therapy could possibly be 
applied to veterinary medicine as well. 
In conclusion, miRNA research is a rapidly expanding field with seemingly 
endless possibilities.  The domestic dog should not be overlooked as science progresses.  
Its value to human studies is hopefully obvious and will continue to grow as 
relationships between veterinarians and researchers are formed.  With the establishment 
of tumor banks and the advancement of genetic tools, research will be expedited and 
improved.  By working together the cure can be found. 
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